GlassScriptPhysician profile
Mark W Westberg
NPI 1952362394
$1,494.90
in general payments reported to CMS, 2019-2025
32 companies · $16.29 in 2025
The $16.29 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,082 · 2020: $174 · 2021: $45.95 · 2022: $177 · 2025: $16.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $165.44 | 2019-2020 | |
| Seagen INC. | $123.76 | 2019-2020 | |
| Pfizer INC. | $114.87 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $113.75 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $94.87 | 2019-2025 | Opdivo |
| Agios Pharmaceuticals, INC. | $93.55 | 2019 | |
| Amgen INC. | $73.65 | 2019-2022 | |
| Genentech USA, INC. | $70.62 | 2019 | |
| Incyte Corporation | $51.59 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $45.57 | 2019-2021 | |
| Genzyme Corporation | $42.69 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.23 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.15 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $37.16 | 2019-2020 | |
| Daiichi Sankyo INC. | $34.81 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $34.52 | 2019 | |
| Celgene Corporation | $33.89 | 2019 | |
| Abbvie INC. | $28.88 | 2019-2020 | |
| Puma Biotechnology, INC. | $28.43 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $26.92 | 2019 | |
| Tesaro, INC. | $26.46 | 2019 | |
| Exelixis INC. | $26.21 | 2019 | |
| Eisai INC. | $25.16 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $19.88 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $17.28 | 2019 | |
| Dova Pharmaceuticals | $15.09 | 2019 | |
| Glaxosmithkline, LLC. | $12.97 | 2022 | |
| Jazz Pharmaceuticals INC. | $12.48 | 2019 | |
| Rigel Pharmaceuticals, INC. | $12.43 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $12.21 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11.34 | 2019 | |
| Array Biopharma INC | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Westberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.